US › Healthcare

Karyopharm Therapeutics Inc (KPTI)

US · Healthcare · Biotechnology

$0.39+11.11%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$33.4M

Revenue YoY

-11.9%

Net profit

$-67.0M

EPS

$-2.32

EPS estimate

$-1.53

Net margin

-200.5%

EPS came in at -2.32 against a street estimate of -1.53 — a miss of 51.6%.

Key statistics

Market cap

$7.1M

Forward P/E

0.0

P/B

12.05

Book value

$-14.56

EPS (TTM)

$-14.33

52-week high

$10.99

52-week low

$0.32

50-day MA

$1.57

200-day MA

$6.46

Beta

1.04

Analyst view

Analysts rate Karyopharm Therapeutics Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $7.25.

Shareholding

Insiders

4.67%

Institutions

95.87%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	8.45%
Adage Capital Partners Gp LLC	6.71%
The Goldman Sachs Group Inc	6.28%
BlackRock Inc	6.26%
Kalehua Capital Management LLC	6.05%
Vanguard Capital Management, LLC	4.23%
Catalio Capital Management, LP	4.15%
Avidity Partners Management LP	4.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Karyopharm Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.